{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-26-000059","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2026-06-10T22:39:35+00:00","discovered_at":"2026-06-11T10:05:00.277028+00:00","generated_at":"2026-06-11T10:08:15.889399+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiora shareholders approve 1.5M share increase to 2024 equity incentive plan","bullets":["Stockholders approved amendment to 2024 Equity Incentive Plan, increasing authorized shares by 1,500,000.","Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle re-elected as Class II directors with >1M votes for each.","Non-binding advisory vote on executive compensation approved: 1,019,325 for, 21,670 against.","Ratification of Haskell & White LLP as auditor for FY 2026: 2,358,943 for, 5,403 against."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-26-000059","json":"https://secwatch.observer/filing/0001372514-26-000059.json","markdown":"https://secwatch.observer/filing/0001372514-26-000059.md","text":"https://secwatch.observer/filing/0001372514-26-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000059/0001372514-26-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000059/kprx-20260610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:08:15.889399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e4a687f0cab764088bc778138fb609a23b01d1b","claim":"KIORA PHARMACEUTICALS INC shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-10 meeting.","evidence_excerpt":"The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,019,325 21,670 4,674 1,320,660","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000059/0001372514-26-000059-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"25c27dddd49e682c516e388957ba28ccbfe07571","claim":"KIORA PHARMACEUTICALS INC shareholders approved Election of Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle as Class II Directors at the 2026-06-10 meeting.","evidence_excerpt":"The results of the election were as follows: Name Votes For Votes Withheld Broker Non-Votes Lisa Walters-Hoffert 1,037,950 7,719 1,320,660 Aron Shapiro 1,030,543 15,126 1,320,660 Praveen Tyle, Ph.D. 1,029,403 16,266 1,320,660","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000059/0001372514-26-000059-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"8655e32164cb74f5880f5485709c3525ed47c1b9","claim":"KIORA PHARMACEUTICALS INC shareholders approved Approval of the amendment of the 2024 Equity Incentive Plan to increase the maximum number of shares authorized for issuance by 1,500,000 shares at the 2026-06-10 meeting.","evidence_excerpt":"The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 732,106 311,987 1,576 1,320,660","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000059/0001372514-26-000059-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"971cb8ea076ea5c889c769d662b8aba0b79c2c6b","claim":"KIORA PHARMACEUTICALS INC shareholders approved Ratification of the appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for fiscal year 2026 at the 2026-06-10 meeting.","evidence_excerpt":"The results of the vote were as follows: Votes For Votes Against Votes Abstained 2,358,943 5,403 1,983","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000059/0001372514-26-000059-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}